Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | TTR | P02766 | 1/20 | 0.67 |
| ▸ | PPOX | P50336 | 1/20 | 0.67 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | DTYMK | P23919 | 1/20 | 0.47 |
| ▸ | PYGL | P06737 | 2/20 | 0.46 |
| ▸ | PYGM | P11217 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10784715 | 0.88 | TDP1 (0.58) | TDP1MEN1KMT2ATTRPPOX | |
| SCHEMBL87462 | 0.86 | TDP1 (0.77) | TDP1MEN1KMT2ATTRPPOX | |
| SCHEMBL10786312 | 0.86 | MEN1 (0.73) | TDP1MEN1KMT2ATTRPPOX | |
| SCHEMBL2730973 | 0.86 | TDP1 (0.76) | TDP1MEN1KMT2ATTRPPOX | |
| SCHEMBL10663721 | 0.85 | TDP1 (0.69) | TDP1MEN1KMT2ATTRPPOX | |
| SCHEMBL11004062 | 0.85 | MEN1 (0.72) | TDP1MEN1KMT2ATTRPPOX | |
| SCHEMBL10784186 | 0.85 | MEN1 (0.71) | TDP1MEN1KMT2ATTRPPOX | |
| SCHEMBL11275207 | 0.85 | MEN1 (0.71) | TDP1MEN1KMT2ATTRPPOX | |
| SCHEMBL28090366 | 0.84 | TDP1 (0.55) | TDP1MEN1KMT2ATTRPPOX | |
| SCHEMBL8764277 | 0.84 | MEN1 (0.81) | TDP1MEN1KMT2ATTRPPOX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116571189-B | Preparation process of 5- (2-chloro-4- (trifluoromethyl) phenoxy) -2-nitrobenzoic acid | 江苏长青农化南通有限公司 | 2024-04-02 | — | — | CN | claimed |
| CN-116571189-A | Preparation process of 5- (2-chloro-4- (trifluoromethyl) phenoxy) -2-nitrobenzoic acid | 江苏长青农化南通有限公司 | 2023-08-11 | — | — | CN | claimed |
| US-8129381-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129381-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129381-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-06 | — | — | US | disclosed |
| US-20090281128-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-11-12 | — | — | US | disclosed |
| US-20090281128-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-11-12 | — | — | US | disclosed |
| US-20090281128-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-11-12 | — | — | US | disclosed |
| US-7553852-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-06-30 | — | — | US | disclosed |
| US-7553852-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-06-30 | — | — | US | disclosed |
| US-7553852-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-06-30 | — | — | US | disclosed |
| CN-100503572-C | Caspase inhibitors and uses thereof | VERTEX PHARMA (US) | 2009-06-24 | — | — | CN | disclosed |
| CN-1675184-A | Caspase inhibitors and uses thereof | VERTEX PHARMA (US) | 2005-09-28 | — | — | CN | disclosed |
| EP-1539701-A1 | CASPASE INHIBITORS AND USES THEREOF | Vertex Pharmaceuticals Incorporated (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20040072850-A1 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2004-04-15 | — | — | US | disclosed |
| WO-2004002961-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-01-08 | — | — | WO | disclosed |
| WO-2004002961-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072850-A1 | Caspase inhibitors and uses thereof | CASP1, CASP5, CASP2 | TDP1 230/4885MEN1 2371/4885KMT2A 4370/4885 |
| US-20090281128-A1 | CASPASE INHIBITORS AND USES THEREOF | CASP1, CASP5, CASP3 | TDP1 289/4885MEN1 2896/4885KMT2A 4329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.